article_snippet.sent: Clinical trials show that olaparib can delay the moment when disease gets dangerously out of control.
article_snippet.sent: The London trial of olaparib, which is owned by AstraZeneca, was led by researchers at the Institute of Cancer Research and the Royal Marsden hospital.
article_snippet.sent: Olaparib is the first cancer drug to target inherited genetic mutations.
article_snippet.sent: Olaparib is one of the first of a new class of drugs called PARP inhibitors.
article_snippet.sent: Olaparib became the first of a new class of drugs called PARP inhibitors to be granted approval last month for use in ovarian cancer by the European Commission and the US Food and Drug Administration.
article_snippet.sent: The drug, olaparib, is the first cancer drug to target inherited genetic mutations.
article_snippet.sent: These encouraging results show that olaparib could be the next drug to add to those already available.
article_snippet.sent: the Institute of Cancer Research will now decide whether olaparib should become widely available on the NHS.
highlights_snippet.sent: Olaparib is the first cancer drug to target inherited genetic mutations .
  